American Capital Advisory’s Recursion Pharmaceuticals RXRX Stock Holding History

American Capital Advisory’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200	Closed	-$976	–	1131
2025 Q3	$976	Hold	200	–	–	﹤0.01%	544
2025 Q2	$1.01K	Hold	200	–	–	﹤0.01%	495
2025 Q1	$1.06K	Hold	200	–	–	﹤0.01%	423
2024 Q4	$1.35K	Hold	200	–	–	﹤0.01%	414
2024 Q3	$1.32K	Hold	200	–	–	﹤0.01%	403
2024 Q2	$1.97K	Buy	+200	New	+$1.74K	﹤0.01%	355
2024 Q1	–	Sell	-200	Closed	-$1.97K	–	503
2023 Q4	$1.97K	Buy	+200	New	+$1.43K	﹤0.01%	355

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

American Capital Advisory's RXRX Position: Q4 2025 in Review

American Capital Advisory sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 200 shares — an estimated $976 sold.

American Capital Advisory first reported a position in RXRX in Q4 2023 and held it in 7 quarters. The position peaked at $1.97K in Q2 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

American Capital Advisory reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
American Capital Advisory sold 200 Recursion Pharmaceuticals shares in Q4 2025, an estimated $976.
American Capital Advisory first reported a position in Recursion Pharmaceuticals in Q4 2023 and held it in 7 quarters.
American Capital Advisory's Recursion Pharmaceuticals position peaked at $1.97K in Q2 2024.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on American Capital Advisory's 13F filing for Q4 2025, filed 30 Jan 2026.